Table 1.
Vaccination characteristics of study participants
| Received third covid-19 vaccine dose during pregnancy (n=18 491) | Did not receive third covid-19 vaccine dose during pregnancy (n=14 198) | |
| Time in days, (weeks) between second dose and LMP: | ||
| <56 days (<8 weeks) | 6544 (35.4) | 6380 (44.9) |
| 56 to <84 days (8 to <12 weeks) | 3555 (19.2) | 2764 (19.5) |
| 84 to <112 days (12 to <16 weeks) | 3350 (18.1) | 2466 (17.4) |
| 112 to <140 days (16 to <20 weeks) | 2770 (15.0) | 1715 (12.1) |
| 140 to <168 days (20 to <24 weeks) | 1215 (6.6) | 552 (3.9) |
| ≥168 days (≥24 weeks) | 1057 (5.7) | 321 (2.3) |
| Median days | 77 (40-115) | 62 (30-100) |
| Median weeks | 11.0 (5.7-16.4) | 8.9 (4.3-14.3) |
| Vaccine products received for primary covid-19 series: | ||
| BNT162b2+BNT162b2* | 11 438 (61.9) | 9188 (64.7) |
| mRNA-1273+mRNA-1273* | 3407 (18.4) | 3009 (21.2) |
| BNT162b2+mRNA-1273 or mRNA-1273+BNT162b2† | 3361 (18.2) | 1877 (13.2) |
| Other‡ | 285 (1.5) | 124 (0.9) |
| Time in days, weeks, between second dose and third dose: | ||
| <168 days (<24 weeks) | 1132 (6.1) | — |
| 168 to <196 days (24 to <28 weeks) | 7945 (43.0) | — |
| 196 to <224 days (28 to <32 weeks) | 5030 (27.2) | — |
| ≥224 days (≥32 weeks) | 4384 (23.7) | — |
| Median days | 196 (182-221) | — |
| Median weeks | 28.0 (26.0-31.6) | — |
| Trimester when third covid-19 dose received: | ||
| First | 5484 (29.7) | — |
| Second | 11 332 (61.3) | — |
| Third | 1675 (9.1) | — |
| Median gestational age in days | 126 (91-163) | — |
| Median gestational age in weeks | 18.0 (13.0-23.3) | — |
| mRNA vaccine received for third dose: | ||
| BNT162b2 (Comirnaty, Pfizer-BioNTech) | 11 281 (61.0) | — |
| mRNA-1273 (Spikevax, Moderna) | 7210 (39.0) | — |
Data are number (percentage) or median (interquartile range). LMP=last menstrual period; mRNA=messenger RNA.
*Same type of mRNA vaccine for dose one and dose two (homologous mRNA series).
†Different type of mRNA vaccine for dose one and dose two (heterologous mRNA series).
‡AstraZeneca/Oxford's covishield Novavax’s nuvaxovid covid-19 vaccine; unspecified.